Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report

Çiçek, Erdinç; Çiçek, İsmet Esra; Uğuz, Faruk

doi:10.9758/cpn.2017.15.2.184

Cited by 6 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The blockage of α1 receptors results in vasodilation with a consequential increase in hydrostatic pressure in the capillaries that could facilitate the onset of oedema ( 69 ). Also, the antagonistic action on 5HT2 receptors could be associated to oedema due to the increase in cyclic adenosine monophosphate concentrations, leading to the relaxation of vascular smooth muscle ( 70 ).…”

Section: Discussionmentioning

confidence: 99%

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database

et al. 2023

View full text Add to dashboard Cite

IntroductionLong-acting injectable antipsychotics (LAIs) have proven to be effective in the maintenance treatment of patients suffering from schizophrenia, and their safety and tolerability profiles represent a key factor in their long-term use and choice in clinical practice. Paliperidone palmitate (PP) is the only second-generation LAI (SGA-LAI), available in both one- (PP1M) and 3-month (PP3M) formulations. However, real-world prospective studies on PP1M and PP3M are still few and mostly conducted on small samples. In this context, we aimed to better define the safety and tolerability profile of PP using real world pharmacovigilance data.MethodsWe retrospectively analyzed the publicly available data regarding Individual Case Safety Reports (ICSRs), presenting PP1M and/or PP3M as suspected drugs, reported on EUDRAVigilance between 2011 and June 30th, 2022. ICSRs relative to at least one SGA-LAI other than PP, reported between 2003 and June 30th, 2022, were also examined as reference group. Data were evaluated with a descriptive analysis, and then, as disproportionality measures, crude reporting odds ratio (ROR) and 95% confidence interval (CI) were calculated.ResultsA total of 8,152 ICSRs met the inclusion criteria, of those 77.7% (n = 6,332) presented as suspected drug PP1M, 21.2% (n = 1,731) PP3M, while 89 cases indicated both PP1M and PP3M. Significantly higher probabilities of reporting in PP-related reports were observed for the primary Standardized MedDRA Queries “Sexual Dysfunctions” (ROR = 1.45; 95% CI 1.23-1.70), “Haemodynamic oedema, effusions and fluid overload” (ROR = 1.42; 1.18-1.70), as well as “Fertility disorders” (ROR = 2.69; 1.51-4.80).DiscussionOur analysis indicates that the tolerability and safety profiles of PP are in line with what is known for the other SGA-LAIs. However, differences regarding endocrine system ADRs have been noticed. The results presented in this work do not discourage the prescription of SGA-LAI formulations but aim to enhance their safety.

show abstract

Section: Discussionmentioning

confidence: 99%

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The NADRPS score indicates a probable association between drug use and edema (4). Edema has been reported with several longacting injectable antipsychotics such as risperidone (6) and paliperidone palmitate (7). The mechanism by which ZDLI and antipsychotics could cause edema has not been fully elucidated.…”

Section: Discussionmentioning

confidence: 99%

Facial and Peripheral Edema Associated with Zuclopenthixol Decanoate Longacting Injectable: A Case Report

Örüm¹,

Kara²

2019

MJWBS

View full text Add to dashboard Cite

Beta blokerler, kalsiyum kanal blokerleri, non-steroid anti inflamatuvar ilaçlar, bazı hormonal ilaçlar ve antipsikotikler yüz ve periferik ödeme neden olabilir ancak antipsikotiklerin uzun etkili depo enjeksiyon formlarına bağlı ödem nadir görülmektedir. Risperidon ve paliperidonun uzun etkili enjekte edilebilir formlarından kaynaklı ödem ile ilişkili olgu sunumları bulunmaktadır. Bildiğimiz kadarıyla, zuklopentiksol dekanoat uzun etkili depo enjeksiyon ile ilişkili yüz ödemi bildirilmemiştir. Bu olgu sunumunda, zuklopentiksol dekanoat uzun etkili enjeksiyon ile tedavi sonrası yüz ve bilateral periferik ödem gelişen bir kadın hasta sunuldu.

show abstract

Paliperidone

2017

Reactions Weekly

View full text Add to dashboard Cite

Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report

Cited by 6 publications

References 17 publications

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database

Facial and Peripheral Edema Associated with Zuclopenthixol Decanoate Longacting Injectable: A Case Report

Paliperidone

Contact Info

Product

Resources

About